Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Back to 2010: England's New CDF To Go Ahead

This article was originally published in Scrip

Executive Summary

England's new Cancer Drugs Fund is to go ahead with little change to proposals that have proved unpopular with companies. The Association of the British Pharmaceutical Industry says the new system will take patients and companies back to the situation in 2010 before the CDF was set up and that two thirds of CDF-financed drugs will be unavailable by the end of the year. Eisai has slammed the new fund, warning that drugs approved after the CDF closed its doors to funding new products will float in limbo with no clear means of getting to patients.


Related Content

Eisai Says Lenvatinib Lost in UK Market Access Maze Due To NICE Inaction
NICE In CDF Rethink Says OK To Bosulif For General NHS Use In CML
NICE Rejects BMS' Opdivo As Adult Kidney Cancer Treatment





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts